Available to SourceHuman Prescription DrugOncology & Specialty

Rinvoq (Upadacitinib)

15 mg/1 · Extended-Release Tablet

By AbbVie Inc.

Upadacitinib · Extended-Release Tablet · 15 mg

NDC: 0074-2306
Route: Oral
Therapeutic class: Janus Kinase Inhibitor , Janus Kinase Inhibitors [MoA]
Marketing category: NDA

Package sizes

14 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2306-70)NDC 0074-2306-70Available to Order
30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2306-30)NDC 0074-2306-30Available to Order

Request This Medication

*Expect a reply within 2 business hours with availability and pricing.

Additional information

Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.

Request a quote

Request this medication.

Pick the package size you need and we’ll respond with availability, lot details, dating, and pricing within 2 business hours. Mark it as Rush or Emergency if you need it faster.

DSCSA-compliant pedigree on every order
Cold-chain capable where applicable
Same-day fulfillment available for urgent needs

Related in Oncology & Specialty

See all →

Rinvoq (Upadacitinib)

Package sizes

Additional information

Request this medication.

Related in Oncology & Specialty

Verzenio (Abemaciclib)

Verzenio (Abemaciclib)

Verzenio (Abemaciclib)

Verzenio (Abemaciclib)